Autoimmunity & Inflammation
Rheumatoid Arthritis
An immune attack on joints that quietly reaches the whole body
Rheumatoid arthritis is an autoimmune disease in which the immune system inflames the lining of the joints, causing pain, stiffness and, if uncontrolled, joint damage. Its inflammation also reaches the lungs, blood vessels, blood and heart, which is why RA shortens healthspan unless it is controlled early and completely.
Also known as: RA
By the numbers
1.5x
cardiovascular mortality vs general population
Source: Avina-Zubieta et al., Arthritis Rheum 2008
Animated explainer
See it happen inside the body
Educational animation based on published research. It is not medical advice and does not replace care from your own clinician.
Whole-body impact
The spillover effect
Chronic inflammation rarely stays in one place. Tap any organ to see how this condition reaches beyond its starting point.
Joints
Synovitis causes symmetric pain, swelling and morning stiffness, classically in the small joints of the hands and feet; uncontrolled inflammation erodes cartilage and bone.
Lungs
Interstitial lung disease scars the lung tissue; in a population-based cohort the lifetime risk was 7.7% in RA versus 0.9% without RA, and RA-ILD nearly tripled the risk of death.
Heart and arteries
Chronic inflammation accelerates atherosclerosis, raising the risk of heart attack and stroke; cardiovascular death is about 50% more common than in the general population.
Blood lipids
The 'lipid paradox': active inflammation lowers measured cholesterol, yet cardiovascular risk rises, so a 'good' cholesterol number can be misleading in active RA.
Spleen and blood
Felty's syndrome, seen in about 1-3% of people with RA, combines seropositive RA, an enlarged spleen and low neutrophil counts, raising infection risk; anemia of chronic inflammation is far more common.
Skin
Firm rheumatoid nodules can form over pressure points such as the elbows, and are a marker of more severe, seropositive disease.
Blood vessels
Rheumatoid vasculitis, now uncommon with modern treatment, inflames small and medium vessels and can cause skin ulcers, nerve damage and digital infarcts.
Eyes
Dry eye is common, and scleritis, a painful inflammation of the white wall of the eye, can threaten vision and signals systemic disease activity.
The biology
How it works
In RA, the immune system loses tolerance to the body's own proteins, often years before symptoms, and antibodies such as rheumatoid factor and anti-CCP appear in the blood. Activated T cells and B cells migrate into the synovium, the thin lining of the joint, where they recruit macrophages and fibroblast-like cells. These cells release inflammatory messengers including TNF, IL-6 and others, and the synovium thickens into an invasive tissue called pannus that erodes cartilage and bone. The same circulating cytokines act far beyond the joint: they activate blood vessel walls, alter cholesterol handling in the liver, suppress red blood cell production and drive scarring in the lung. That is why RA is best understood as a systemic inflammatory disease with the joints as its most visible target.
Healthspan
Why it matters for longevity
RA is not only a joint disease; it is a cardiovascular and pulmonary risk factor. A meta-analysis of observational studies found cardiovascular mortality roughly 50% higher in people with RA (meta-SMR 1.50), with similar excess for ischemic heart disease and stroke. Interstitial lung disease accounts for an estimated 13% of the excess mortality in RA. Because inflammation lowers measured cholesterol while raising risk, standard calculators can underestimate danger. The encouraging news is that treat-to-target care, aiming for remission or low disease activity, is the central principle of current EULAR guidance, and controlling inflammation early is one of the most powerful ways to protect long-term function and healthspan.
The Four Quadrant Protocol™
How it connects across all four quadrants
Autoimmunity, metabolism, hormones and cellular health feed each other. This is why we treat the whole system, not one lab value.
Quadrant 02 Metabolic & Obesity Health
Inflammatory cytokines disturb lipid and glucose metabolism, producing the RA lipid paradox and amplifying cardiovascular risk; visceral fat adds its own inflammatory load.
Quadrant 03 Hormonal Optimization
RA is about two to three times more common in women and often shifts around pregnancy and menopause, and long-term glucocorticoids suppress the adrenal axis and bone-building hormones.
Quadrant 04 Regenerative & Cellular Health
Persistent inflammation erodes cartilage and bone and accelerates muscle loss, so preserving joint tissue, muscle and bone is a core healthspan goal.
Research and longevity frontier
What science is testing now
Emerging therapies and active trials. Listed for education only. Many are not yet approved and are not offered as treatments here.
Abatacept to intercept RA before it starts (APIPPRA)
Phase 2b completed; investigational for prevention
In high-risk, antibody-positive people with joint pain, 12 months of abatacept reduced progression to RA during treatment (arthritis-free at 12 months: 92.8% vs 69.2% placebo), though the gap narrowed after stopping.
ORAL Surveillance JAK inhibitor safety trial
Completed post-marketing RCT (2022)
In patients 50 or older with at least one cardiovascular risk factor, tofacitinib did not meet non-inferiority to TNF inhibitors for major cardiovascular events or cancer, reshaping how JAK inhibitors are selected for older, higher-risk patients.
Vitamin D and omega-3 for autoimmune prevention (VITAL)
Completed RCT (2022)
In about 26,000 older adults, five years of vitamin D3 2000 IU per day was associated with fewer confirmed new autoimmune diseases, including RA; it is a prevention signal, not a treatment for established RA.
Common questions
Frequently asked
If my cholesterol is low, am I protected from heart disease with RA?
Not necessarily. Research on the 'lipid paradox' shows that active inflammation can push cholesterol down while cardiovascular risk goes up. Heart risk in RA should be judged together with disease activity, and EULAR guidance recommends regular cardiovascular risk assessment.
Why does a joint disease affect my lungs?
The same immune process that inflames joints can drive inflammation and scarring in lung tissue. Interstitial lung disease is one of the most important RA complications, so a new cough or breathlessness deserves prompt evaluation.
Can RA go into remission?
Yes, remission or low disease activity is the stated treatment target in current EULAR recommendations, and many people reach it with early, adjusted therapy. Treatment is individualized and should be guided by a rheumatologist.
Peer-reviewed sources
Published evidence
Every claim on this page is drawn from peer-reviewed research, guidelines and registered clinical trials. Open any source to read the original.
guideline
Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3-18.
meta-analysis
Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690-1697.
cohort
Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-487.
cohort
Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583-1591.
review
Owlia MB, Newman K, Akhtari M. Felty's syndrome, insights and updates. Open Rheumatol J. 2014;8:129-136.
RCT
Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316-326.
RCT
Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452.
RCT
Cope AP, Jasenecova M, Vasconcelos JC, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838-849.
Educational website
fourquadrantprotocol.com is an educational resource. Content summarizes published research for learning purposes only. It is not medical advice, diagnosis or treatment, and it does not create a doctor-patient relationship. Always talk with your own clinician before changing any treatment. Questions: info@fourquadrantprotocol.com
Ready to look at the whole picture?
Work with Dr. Faisal Tahir to map your own four quadrants.
Book a consultation